ePrints

Platelet hyperactivity in type 2 diabetes: Role of antiplatelet agents

Lookup NU author(s): Dr Arun Natarajan, Professor Azfar Zaman, Emerita Professor Sally Marshall

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Type 2 diabetes mellitus increases atherothrombotic risk. Platelets in individuals with diabetes show increased activity at baseline and in response to agonists, ultimately leading to increased aggregation. Increased expression of platelet surface adhesion molecules and receptors, enhanced production of thromboxane and thrombin and disturbances in platelet calcium homeostasis are well documented. As intra-arterial thrombi are initiated by platelets, strategies to limit acute thrombotic events have largely focused on antiplatelet agents. Aspirin remains the cornerstone of antiplatelet therapy but appears to have limited benefit in diabetes. Use of thienopyridines and platelet glycoprotein IIb/IIa receptor inhibitors has been shown to benefit high-risk patient populations. This review summarises the different platelet abnormalities characterised in diabetes and the role of currently used antiplatelet agents.

Publication metadata

Author(s): Natarajan A, Zaman AG, Marshall SM

Publication type: Article

Publication status: Published

Journal: Diabetes and Vascular Disease Research

Year: 2008

Volume: 5

Issue: 2

Pages: 138-144

ISSN (print): 1479-1641

ISSN (electronic): 1752-8984

Publisher: Sage Publications Ltd.

URL: http://dx.doi.org/10.3132/dvdr.2008.023

DOI: 10.3132/dvdr.2008.023

Altmetrics

Share